Description
UrgoClean Ag is an innovative dressing in non-woven fabric, absorbent and gelling, made up of polyacrylate poly-absorbent fibers that guarantee a complete cleansing and debridement action (from slough, fibrin, exudate, bacterial residues and biofilm) and a colloidal lipid matrix TLC-Ag which has an antimicrobial action. The combined action of the TLC-Ag matrix and the poly-absorbent fibers allows an antimicrobial, anti-biofilm and complete cleansing action.
- The TLC-Ag matrix of UrgoClean Ag gels in contact with the exudate of the lesion, reducing the bacterial load of the lesion with a fast and broad-spectrum action (tested on 36 bacterial strains and 4 yeasts, including bacterial strains resistant to antibiotics -MRSA, ERV, ESBL).
- In contact with the lesion, the poly-absorbent fibers of UrgoClean Ag gel and break the matrix of the biofilm, allowing the silver ions to carry out their bactericidal action within the biofilm. The combined action of the poly-absorbent fibers and the TLC-Ag matrix has been shown to effectively reduce the concentration of MRSA and P.aeruginosa textile bacteria within 24 hours and for 7 days (reduction of biofilm> 99.99%). The anti-biofilm action of UrgoClean Ag is superior compared to the Hydrofibra Ag + Extra and compared to the dressing with DACC.
- UrgoClean Ag removes all those factors that favor bacterial proliferation and that can limit the action of silver. The poly-absorbent fibers of UrgoClean Agabsorb and trap slough, exudate and biofilm residues through an electrostatic mechanism. UrgoClean Ag has been clinically demonstrated after 4 weeks of treatment to reduce slough by 62.5% and cleanse 59% of lesions (lesionedetersa = lesion covered with less than 30% slough).
- The dressing is removed in one piece thanks to the acrylic core present in the poly-absorbent fibers.
- UrgoClean Ag ensures atraumatic and pain-free treatments thanks to the humid environment provided by the TLC-Ag3 matrix.
- UrgoClean manages minor bleeding due to its haemostatic properties.
- UrgoClean Ag can be cut to size and can be used with a secondary dressing.
- UrgoClean Ag can be combined with compression therapy, when prescribed.

Composition
Antimicrobial dressing composed entirely of poly-absorbent polyacrylate fibers, detergents and gelling agents, and a collidal lipid micro-adherent matrix TLC-Ag (TLC-Ag: Lipido-Colloidal Technology, composed of carboxymethylcellulose particles, lipid substances and salts of silver) to fight local infection through a combined antimicrobial / anti-biofilm and thorough cleansing action. UrgoClean Ag has the ability to cleanse and keep the lesion clean.

How to use
Cleanse the wound using conventional care protocol, then rinse with saline. If an antiseptic was previously used, carefully rinse the lesion with saline before applying UrgoClean Ag. The use of UrgoClean Ag does not neglect the need for mechanical debridement, if necessary. Remove the protective tabs and apply the micro-adherent part of UrgoClean Ag in contact with the wound and to the periwound skin. If necessary, UrgoClean Ag can be cut with sterilizer scissors to adapt the size of the dressing to the size of the wound. It is recommended to use a bandage to secure the dressing and ensure that it remains in place. In addition, it is possible to cover UrgoClean Ag with a secondary dressing suitable for the location of the lesion and the degree of exudation. If prescribed, apply compression therapy. The UrgoClean Ag dressing should be replaced every 1-2 days at the start of treatment, and thereafter as needed (up to 7 days) depending on the amount of exudate and the clinical state of the wound. Treatment with Urgoclean Ag should not last more than one month.
The micro-adherent matrix TLC-Ag present in UrgoClean Ag can adhere to latex surgical gloves. Consequently, it is recommended to moisten the gloves with normal saline solution for easier handling of the dressing. During the debridement process, the lesion may appear larger than usual. This is due to the effective removal of the slough.

Warnings
Contraindicated in cases of known sensitivity to silver.
UrgoClean Ag is not recommended for use as a surgical sponge for highly exuding wounds.
Do not use UrgoClean Ag in combination with oxygen peroxide, organ-mercury based antiseptics or antiseptics containing hexamidine.
Do not use on patients undergoing open magnetic resonance imaging (MRI).
Treatment with UrgoClean Ag must be performed under medical supervision.
The use of UrgoClean Ag does not go beyond the need for a systemic antibacterial treatment for the infection, in line with the local protocol.
Concomitant use with other local treatments is not recommended.
Avoid contact with conductive electrodes or gels used in case of EEG or ECG.
Healthcare professionals should be made aware of the lack of information, scant specific data on the prolonged and repeated use of silver dressings, especially in children and infants.
In the absence of specific clinical data, use in pregnant or lactating women is not recommended.
Sterile individual packs, single use only: the reuse of a single use pack may involve risk of infection.
Do not resterilize the dressing.
Before use, make sure that the sterile protective film is intact. Do not use in case of damaged package.

storage
Store at room temperature away from sources of light and heat.
Validity for intact packaging: 36 months.

Format
Available in:
-pack of 5 pieces, size: 6 cm x 6 cm;
-package of 5 pieces, size: 10 cm x 10 cm;
-pack of 5 pieces, size: 15 cm x 15 cm;
- pack of 10 pieces, size: 6 cm x 6 cm;
- pack of 10 pieces, size: 10 cm x 10 cm;
-package of 10 pieces, size: 15 cm x 15 cm.

Cod. 552093, 552273, 552095, 552094, 552274, 551749

Bibliography
Lazareth I., et al., The Role of a Silver Releasing Lipido-colloid Contact Layer inVenous Leg Ulcers Presenting Inflammatory Signs Suggesting Heavy Bacterial Colonization: Results of a Randomized Controlled Study. WOUNDS 2008; 20 (6): 158–166.
Meaume S., et al., Evaluation of two fibrous wound dressings for the management of legulcers: Results of a European randomized controlled trial (EARTH RCT). J Wound Care, Vol23, No 3, March 2014, 105-116.
Dalac S., et al., Clinical evaluation of a dressing with poly absorbent fibers and asilver matrix for managing chronic wounds at risk of infection: a non-comparative trial. J Wound Care, Vol 25, No 9, September 2016.
J. Dissemond, Results of a national multicentre observational trial on desloughingproperties on wounds at risk or with signs of a local infection with a polyabsorbentdressing with silver. Oral communication. EWMA 2017.
Desroche N. et al., Characterization of the antimicrobial spectrum and anti-biofilmactivity of a new silver-containing dressing with poly-absorbent fibers and antimicrobialsilver matrix. EWMA Poster May 2016.
Desroche N., et al., Antibacterial properties and reduction of MRSA biofilm with adressing combining poly-absorbent fibers and a silver matrix. J Wound Care, Vol 25, No10, October 2016.
Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care. 2018 Feb; 27 (2): 102-13.
Desroche N. et al, Evaluation of in vitro anti-biofilm activities of two dressings with poly-absorbent dressing fibers and a DACC-coated dressing. EWMA 2017 Poster.
UrgoClean Ag data on file.
Pernot JM, et al., Interactions between poly-absorbent fibers and fibrin. PosterJournées Cicatrisations. January 2017.
Percival SL, et al. Slough and biofilm: removal of barriers to wound healing bydesloughing. J Wound Care. 2015 Nov; 24 (11): 498.500-3.506-10.